SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024 , at 2:00 p.m.

Vistagen CEO Shawn Singh ; The Goldie Hawn Foundation Founder Goldie Hawn ; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health

Next step in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder achieved as planned SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 23, 2024-- Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 13, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 6, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2024-- Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain

Mental Health America’s highest national certification enhances Vistagen’s ongoing efforts to promote mental health throughout the U.S. SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2024-- Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated

Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 7, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company